220093-41-4Relevant articles and documents
MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES
-
, (2021/11/06)
The present disclosure relates to novel compounds for use in therapeutic treatement of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.
Method for reducing content of diastereoisomer impurity in Ledipasvir intermediate
-
Paragraph 0044; 0045; 0046; 0047, (2016/10/10)
The invention discloses a method for reducing content of a diastereoisomer impurity (Ia) in a Ledipasvir intermediate (1R,3S,4S)-N-t-butyloxycarboryl-2-azabicyalo[2.2.1]heptane-3-carboxylic acid (I). The method comprises the steps of firstly taking a crude product of a compound shown as a formula (I) and containing the diastereoisomer impurity (Ia), dissolving in an organic solvent, adding alkaline organic amine to react with the crude product, separating out a solid, and filtering to obtain an amine salt of the compound shown as the formula (I); acidizing the obtained amine salt in an aqueous phase solution; extracting an obtained aqueous phase, separating out a solid, and separating to obtain the high-purity Ledipasvir intermediate (I). The product obtained by the method has a de value up to more than 99.5 percent, and the yield of more than 80 percent; reaction conditions in the method are mild, raw materials are easy to get, and the method is suitable for industrial application.
Direct asymmetric aldol reactions promoted by (1R, 3S, 4S)-2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid as an organocatalyst
Chen, Wei-Yi
, p. 378 - 380 (2015/03/03)
-